Overview

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-07-11
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to estimate the antitumor efficacy of SOT101 in combination with pembrolizumab in selected tumors.
Phase:
Phase 2
Details
Lead Sponsor:
SOTIO Biotech AG
Treatments:
Pembrolizumab